The AML Delphi Survey is closed. Patients, clinicians, drug developers and regulators have participated.
Make use of our explanatory documentation:
Challenge
At present, several innovative compounds are being tested in clinical trials in order to improve the treatment of Acute Myeloid Leukemia (AML). However, these trials measure different outcomes, thus thwarting their comparability. In addition, the majority of clinical trials do not assess long-term side effects and their influence on the patients’ quality of life. A core outcome set (COS) may assist researchers in selecting outcomes for future trials, thereby promoting harmonization of AML studies and improving clinical management of the disease.
Aim
- To identify a minimum set of outcomes to be measured in future clinical trials in AML, agreed upon by all of HARMONY’s stakeholder groups.
- To enhance the comparability of clinical trials, in addition to improving the clinical management of AML and guiding the collection of registry and real-world data through the use of a COS.
Approach
- This pilot study will use the Delphi method to achieve a consensus on an iteration of a COS for AML in adult patients. A representative panel of stakeholders will be asked to rate the importance of various outcomes in at least three iterative survey rounds.
Impact
- Harmonizing future clinical trials in AML, thus facilitating the comparing and combining of data.
- Guiding the collection of real-world data.
- Improving clinical management by implementing the COS in clinical guidelines and practice.
- Improving patient satisfaction during and after treatment.
- Guiding the process of defining COS’s for other hematologic malignancies (HM).
Project Summary
AML is the most common acute leukemia in adults. Despite recent scientific advances, AML cure rates remain poor, compared to those for other HMs. To improve the treatment of AML, several novel compounds are currently being tested in clinical trials. Unfortunately, these trials are insufficiently comparable because they measure different outcomes. In addition, the majority of trials do not assess long-term side effects and their influence on patients’ quality of life. Defining a core outcome set (COS) may offer a solution to these problems.
A COS is a minimum set of outcomes to be collected in future clinical trials which, ideally, have been agreed upon by all stakeholders. The COS is intended as an international standard to evaluate AML treatments in clinical trials and other research settings (e.g., registry and observational studies). Using a COS will improve the comparability of clinical trials, enhance the consistency of reporting, and reduce selective reporting bias. The COS can also be incorporated into clinical guidelines and be used to improve patient management. This project aims to identify a COS for AML in adult patients that will be accepted by all of HARMONY’s stakeholder groups.
The researchers will use the Delphi method to develop the COS. First, a preliminary list of about 70 outcomes will be created, which will be based on literature research and expert interviews. Next, a panel of stakeholders will be asked to rate the importance of each outcome on the basis of +their personal experiences. This will be done in at least three iterative rounds, using an online survey tool (COMET). After each round, the participants will receive an anonymized summary of the survey results per stakeholder group. This will allow them to revise their answers in the next round. It is expected that the group will converge towards a consensus COS after a number of iterations. The process will be stopped after pre-defined consensus criteria have been achieved.
Panel participants will be recruited from HARMONY Partners, including clinicians, patients, representatives from the pharmaceutical industry, and health authorities. The aim is to recruit equal participant numbers for all stakeholder groups wherever possible. Potential participants will be contacted by email. After completion of this pilot in AML, similar Delphi surveys are planned for the other hematological malignancies that are being studied by the HARMONY Alliance. Finally, a COS applicable to all seven hematological malignancies will be defined.
Download the Delphi AML Study Protocol document to inspect the full outcome list in Annex 1 >
Project Leadership
- Lars Bullinger, Charité, Germany – HARMONY Work Package 2 Lead
- Renate Schulze-Rath, Bayer AG, Germany – HARMONY Work Package 2 Lead
- Rory Goodbody, Abbvie, Ireland – HARMONY Work Package 2 Co-Lead
Project Partnership
- HARMONY Partners from Work Package 2 and 6, active in health service, research, drug development and patient advocacy, including the HARMONY Patient Cluster.
View all of HARMONY’s Research Projects or read more about the HARMONY Alliance, the HARMONY Big Data Platform, and the HARMONY Anonymization Concept of Data.